Recursion Pharmaceuticals to spotlight self-driving lab model at NVIDIA GTC 2026
Recursion Pharmaceuticals spotlights its self-driving lab model at NVIDIA GTC 2026. Explore what this means for AI drug discovery and regulation.
Features & Analysis
Medical Devices & Diagnostics
Could Carterra Inc.’s Vega HT-SPR accelerate fragment and small-molecule discovery without compromising rigor
Find out how Carterra Inc.’s Vega HT-SPR platform could redefine primary screening and reshape early drug discovery workflows.
Pharma & Biotech
Why Brightseed’s glycemic control data could reshape how GLP-1 companion products are evaluated
Peer-reviewed data puts Brightseed’s BioMetaControl under the clinical microscope. Find out what this trial means for GLP-1 companions and metabolic care.
Pharma & Biotech
How Insilico Medicine’s ISM8969 could unlock a new class of neuroinflammatory drugs
Insilico’s AI-designed drug ISM8969 enters Phase 1 for Parkinson’s disease. Find out what this NLRP3 candidate could mean for CNS drug development.
Medical Devices & Diagnostics
Illumina’s Billion Cell Atlas marks inflection point for AI-enabled drug discovery in 2026
Illumina, Inc. has launched the Billion Cell Atlas, a large-scale genetic perturbation dataset designed to serve as foundational infrastructure for artificial intelligence-enabled drug discovery. Announced alongside strategic collaborations with AstraZeneca, Merck, and Eli Lilly and Company, the platform leverages CRISPR-based genome editing and single-cell RNA sequencing across more than 200 disease-relevant cell lines. This marks
Pharma & Biotech
Is insitro’s TherML platform finally delivering on the AI-native promise for biologics and small molecules?
insitro has announced the acquisition of CombinAbleAI and launched its new TherML platform, a modality-agnostic, AI-powered system that integrates small molecules, oligonucleotides, and biologics into a unified therapeutic design stack. The move signals a strategic attempt to industrialize AI-native drug discovery across modalities while reducing late-stage attrition risks. What makes this acquisition different from typical
Pharma & Biotech
Why Revvity’s Signals Xynthetica integration with Lilly TuneLab could reshape biotech AI
Revvity and Lilly team up to scale AI-powered drug discovery. Find out how federated learning could reshape access to predictive models across biotech.
Pharma & Biotech
Eli Lilly taps Chai Discovery to accelerate biologics with AI-generated candidates
Eli Lilly partners with Chai Discovery to deploy AI for antibody drug design. Find out what this means for the future of biologics R&D.
Pharma & Biotech
Enveda’s ENV-6946 enters Phase 1: Can a “multi-biologic in a pill” reshape the future of IBD therapy?
Can Enveda’s ENV-6946 deliver the efficacy of biologics in a pill for IBD? Find out why its triple-cytokine Phase 1 trial is drawing industry attention.
Pharma & Biotech
From Parkinson’s to platform scalability: What’s next for Sinopia’s LEADS technology
Sinopia Biosciences receives NIH grant to expand its LEADS platform. Find out how AI and metabolomics could transform drug discovery.